Fig. 5

Drug combination strategies in NK cells. a Delta scores representing the degree of synergy (see Methods) of the selected drug combinations in NK cell lines. Bar heights indicate mean, and error bars the range of two independent experiments. Drug combinations are ranked according to mean delta score. b Dose–response matrices of percent inhibition achieved at indicated doses of ruxolitinib combined with venetoclax or alisertib in cell lines SNK-6 and KHYG-1. Shown are representative results from one out of two experiments. c Dose–response matrices of delta synergy scores achieved at indicated doses of ruxolitinib combined with venetoclax or alisertib in cell lines SNK-6 and KHYG-1. Shown are representative results from one out of two experiments. d Dose–response curves of percent inhibition achieved at indicated doses of ruxolitinib combined with venetoclax or alisertib in cell lines SNK-6 and KHYG-1. Dots indicate mean and error bars the range of two independent experiments. e Viability percentages for ruxolitinib, venetoclax and alisertib as single agents and in combination across NK cell lines normalized to DMSO and BzCl controls. f Dose–response curves and viability percentages for ruxolitinib, venetoclax, alisertib and combinations in primary NK cells isolated from a patient with a BM NK-cell lymphoproliferation harboring a STAT3 mutation